» Articles » PMID: 39331239

Optimal Cut-off Values and Diagnostic Significance of Clinical Laboratory Indicators in Newly Diagnosed Multiple Myeloma

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2024 Sep 27
PMID 39331239
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aims to identify clinical laboratory parameters for the diagnosis of newly diagnosed multiple myeloma (NDMM), establish optimal cutoffs for early screening, and develop a diagnostic model for precise diagnosis.

Methods: The study conducted a retrospective analysis of 279 NDMM patients and 553 healthy subjects at Zhejiang Province People's Hospital between January 2008 and June 2023. Multifactor LR was employed to explore clinical laboratory indicators with diagnostic value for NDMM, determine optimal cutoff values and contract a diagnostic model. The diagnostic efficacy and clinical utility were evaluated using receiver operating characteristic curves (ROC), sensitivity, specificity, and other indicators.

Results: Multifactor analysis revealed that hemoglobin (Hb), albumin (Alb), and platelet distribution width (PDW) were significant diagnostic factors for NDMM. Optimal cutoff values for Hb, Alb, and PDW in MM diagnosis were determined, and the results showed a significant increase in the probability of NDMM diagnosis when Alb was below 39.3 g/L, Hb was below 11.6 g/dL, and PDW was below 14.1 fL. The diagnostic model constructed from the development cohort demonstrated a high area under the ROC curve of 0.960 (95% CI 0.942-0.978) and exhibited good sensitivity (0.860), specificity (0.957). The area under the curve (AUC) value of the diagnostic model in the external validation cohort was 0.979, confirming its good diagnostic efficacy and generalization.

Conclusions: The optimal cutoff values for Hb, Alb, and PDW and the diagnostic model designed in the study provided good accuracy and sensitivity for the initial screening and diagnosis of NDMM.

Citing Articles

Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.

Mikulski D, Kedzior M, Mirocha G, Jerzmanowska-Piechota K, Witas Z, Wozniak L Cancers (Basel). 2024; 16(21).

PMID: 39518146 PMC: 11545561. DOI: 10.3390/cancers16213709.

References
1.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

2.
Neal R, Tharmanathan P, France B, Din N, Cotton S, Fallon-Ferguson J . Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015; 112 Suppl 1:S92-107. PMC: 4385982. DOI: 10.1038/bjc.2015.48. View

3.
Caers J, Garderet L, Kortum K, ODwyer M, van de Donk N, Binder M . European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018; 103(11):1772-1784. PMC: 6278986. DOI: 10.3324/haematol.2018.189159. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

5.
Laudin G, Levay P, Coetzer B . Globulin fraction and albumin: globulin ratio as a predictor of mortality in a South African multiple myeloma cohort. Int J Hematol Oncol. 2020; 9(3):IJH27. PMC: 7521188. DOI: 10.2217/ijh-2020-0003. View